Parenteral Nutrition Associated Liver Disease Clinical Trial
Official title:
Omegaven Protocol:Intermediate Size Patient Population
Children requiring prolonged courses of PN are at risk for developing PN associated liver disease. We hypothesize that although omega-6 fatty acid emulsions prevent fatty acid deficiency, they are not cleared in a manner similar to enteral chylomicrons and therefore accumulate in the liver and resulting in steatotic liver injury. We further hypothesize that a fat emulsion comprised of omega-3 fatty acids (i.e., fish oil) such as Omegaven® would be beneficial in the management of steatotic liver injury by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00910104 -
Cholestasis Reversal: Efficacy of IV Fish Oil
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01157780 -
Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation
|
N/A | |
| Completed |
NCT00862446 -
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
|
Phase 4 | |
| Completed |
NCT03442361 -
Olive Oil and Soybean 1 Oil Based Intravenous Lipid Emulsions, Liver Chemistry and Clinical Outcomes
|
N/A | |
| Completed |
NCT05181085 -
Study of NST-6179 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02010034 -
Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury
|
N/A | |
| Completed |
NCT05347888 -
How Well do we Feed the Critically Ill Patients
|
||
| Withdrawn |
NCT04807478 -
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
|
||
| No longer available |
NCT02121769 -
Omegaven Expanded Access Protocol
|